Physician profile
John H Healey
NPI 1992781645
$580,056.46
in general payments reported to CMS, 2019-2025
7 companies · $362K in 2025
The $362K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $7,563 · 2021: $27K · 2022: $9,949 · 2023: $626 · 2024: $158K · 2025: $362K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $506K · Consulting Fee: $14K · Food and Beverage: $386 · Travel and Lodging: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $505,570.41 |
| Consulting Fee | $14,244.56 |
| Food and Beverage | $386.16 |
| Travel and Lodging | $190.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $532,951.72 | 2019-2025 | Triathlon, Gmrs |
| Daiichi Sankyo INC. | $31,809.81 | 2019-2021 | |
| Emd Serono Research & Development Institute, INC. | $12,780.00 | 2025 | |
| Musculoskeletal Transplant Foundation INC. | $1,762.32 | 2019-2021 | |
| Emd Serono, INC. | $540.41 | 2025 | |
| Zimmer Biomet Holdings, INC. | $122.64 | 2019 | |
| Octapharma USA, INC. | $89.56 | 2023 | Panzyga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Healey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.